EA200100139A1 - Фармацевтические композиции, содержащие 2-хинолоны - Google Patents

Фармацевтические композиции, содержащие 2-хинолоны

Info

Publication number
EA200100139A1
EA200100139A1 EA200100139A EA200100139A EA200100139A1 EA 200100139 A1 EA200100139 A1 EA 200100139A1 EA 200100139 A EA200100139 A EA 200100139A EA 200100139 A EA200100139 A EA 200100139A EA 200100139 A1 EA200100139 A1 EA 200100139A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
chinolones
compositions containing
tumors
proliferation
Prior art date
Application number
EA200100139A
Other languages
English (en)
Other versions
EA003933B1 (ru
Inventor
Бенуа Жозеф
Франсис Дарро
Жераль Гийоме
Роберт Кисс
Арман Фридман
Original Assignee
Лаборатуар Л.Лафон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборатуар Л.Лафон filed Critical Лаборатуар Л.Лафон
Publication of EA200100139A1 publication Critical patent/EA200100139A1/ru
Publication of EA003933B1 publication Critical patent/EA003933B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine

Abstract

Изобретение относится к фармацевтическим композициям, обладающим активностью в отношении пролифирации клоногенных клеток в опухолях, включающим эффективное количество соединения, выбранного из соединений формулы (I) и (Ia), где X, R, R, R, R, R, Rимеют значения, определенные в п.1 формулы изобретения.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100139A 1998-07-15 1999-07-13 Способ лечения рака, фармацевтические композиции, содержащие 2-хинолоны EA003933B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9809060A FR2781218B1 (fr) 1998-07-15 1998-07-15 Compositions pharmaceutiques comprenant des 2-quinolones
PCT/FR1999/001716 WO2000003990A1 (fr) 1998-07-15 1999-07-13 Compositions pharmaceutiques comprenant des 2-quinolones

Publications (2)

Publication Number Publication Date
EA200100139A1 true EA200100139A1 (ru) 2001-06-25
EA003933B1 EA003933B1 (ru) 2003-10-30

Family

ID=9528650

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100139A EA003933B1 (ru) 1998-07-15 1999-07-13 Способ лечения рака, фармацевтические композиции, содержащие 2-хинолоны

Country Status (22)

Country Link
US (1) US6593342B1 (ru)
EP (1) EP1097138B1 (ru)
JP (1) JP2002520394A (ru)
KR (1) KR20010071859A (ru)
CN (1) CN1195740C (ru)
AT (1) ATE312080T1 (ru)
AU (1) AU766282B2 (ru)
BR (1) BR9912073A (ru)
CA (1) CA2337115A1 (ru)
CZ (1) CZ2001148A3 (ru)
DE (1) DE69931925D1 (ru)
EA (1) EA003933B1 (ru)
FR (1) FR2781218B1 (ru)
HU (1) HUP0103507A3 (ru)
IL (1) IL140437A0 (ru)
NO (1) NO319771B1 (ru)
NZ (1) NZ509076A (ru)
PL (1) PL345550A1 (ru)
SK (1) SK162001A3 (ru)
TR (1) TR200100075T2 (ru)
WO (1) WO2000003990A1 (ru)
ZA (1) ZA200100235B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756383B2 (en) 2000-09-01 2004-06-29 Chiron Corporation Heterocyclic derivatives of quinolinone benimidazoles
ATE386736T1 (de) 2000-09-11 2008-03-15 Novartis Vaccines & Diagnostic Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten
FR2813791B1 (fr) 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
EP1565187A4 (en) 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic CANCER TREATMENT METHODS AND RELATED METHODS
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7960548B2 (en) * 2005-04-29 2011-06-14 The Ohio State University Research Foundation Keratinocyte growth factor receptor—tyrosine specific inhibitors for the prevention of cancer metastatis
CN101223157B (zh) 2005-05-17 2013-03-06 诺瓦提斯公司 合成杂环化合物的方法
CA2636018A1 (en) * 2006-01-30 2007-08-09 Merck & Co., Inc. Inhibitors of fatty acid synthase (fas)
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
EP1860104A1 (en) * 2006-05-22 2007-11-28 Aptanomics Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
JP5133416B2 (ja) 2007-09-14 2013-01-30 オルソー−マクニール−ジャンセン ファーマシューティカルズ， インコーポレイテッド． １’，３’−二置換−４−フェニル−３，４，５，６−テトラヒドロ−２ｈ，１’ｈ−［１，４’］ビピリジニル−２’−オン
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
ES2330495B1 (es) * 2007-11-07 2010-09-20 Consejo Superior De Investigaciones Cientificas (Titular Al 51%) Inhibidores de la enzima o6-alquilguanina-adn-metil-transferasa para el tratamiento del cancer.
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
EP2430031B1 (en) 2009-05-12 2013-04-17 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
AU2011328195B2 (en) 2010-11-08 2015-04-02 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103242231B (zh) * 2013-05-21 2015-10-28 天津青松华药医药有限公司 喹啉类衍生物及其制备方法与应用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PL3431106T3 (pl) 2014-01-21 2021-06-28 Janssen Pharmaceutica Nv Kombinacje zawierające pozytywne modulatory allosteryczne metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
US10646465B2 (en) 2015-12-17 2020-05-12 Biokine Therapeutics Ltd. Small molecules against cancer
US11129824B2 (en) 2015-12-17 2021-09-28 Biokine Therapeutics Ltd. Small molecules for inhibiting chemokine activity and/or cancer cells growth
KR101879992B1 (ko) * 2016-07-29 2018-07-19 국립암센터 c-Myc/Max/DNA 복합체 형성을 억제하는 화합물
KR20220009442A (ko) 2019-05-15 2022-01-24 아론바이오 리미티드 암 치료, 케모카인 활성 억제 및/또는 세포사 유도를 위한 소분자

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2249217A1 (de) * 1972-10-07 1974-04-18 Hoechst Ag Verfahren zum faerben von synthetischen fasermaterialien aus organischen loesemitteln
EP0024638A1 (en) * 1979-08-30 1981-03-11 Byk Gulden Lomberg Chemische Fabrik GmbH Substituted quinolinone-alkanecarboxylic acids, their preparation, and medicaments containing them
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
WO1994002145A2 (en) * 1992-07-22 1994-02-03 Genelabs Technologies, Inc. 2-aryl-4-quinolones as antitumor compounds
ES2088822B1 (es) * 1994-02-24 1997-08-01 Univ Madrid Complutense Nuevos derivados antraquinonicos con actividad antitumoral y sus aplicaciones.
US5726184A (en) * 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity

Also Published As

Publication number Publication date
KR20010071859A (ko) 2001-07-31
EP1097138A1 (fr) 2001-05-09
CN1195740C (zh) 2005-04-06
BR9912073A (pt) 2001-04-10
HUP0103507A2 (hu) 2002-02-28
CZ2001148A3 (cs) 2001-12-12
DE69931925D1 (de) 2006-07-27
SK162001A3 (en) 2002-04-04
US6593342B1 (en) 2003-07-15
FR2781218A1 (fr) 2000-01-21
CA2337115A1 (en) 2000-01-27
TR200100075T2 (tr) 2001-08-21
NO319771B1 (no) 2005-09-12
NO20010228L (no) 2001-03-15
JP2002520394A (ja) 2002-07-09
HUP0103507A3 (en) 2002-05-28
NZ509076A (en) 2003-10-31
IL140437A0 (en) 2002-02-10
FR2781218B1 (fr) 2001-09-07
CN1309639A (zh) 2001-08-22
WO2000003990A1 (fr) 2000-01-27
NO20010228D0 (no) 2001-01-12
PL345550A1 (en) 2001-12-17
AU766282B2 (en) 2003-10-16
ATE312080T1 (de) 2005-12-15
ZA200100235B (en) 2002-01-09
EA003933B1 (ru) 2003-10-30
AU4789199A (en) 2000-02-07
EP1097138B1 (fr) 2005-12-07

Similar Documents

Publication Publication Date Title
EA200100139A1 (ru) Фармацевтические композиции, содержащие 2-хинолоны
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
EA199900936A1 (ru) Фунгицидные трифторметилалкиламинотриазолопиримидины
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA199900366A1 (ru) Гетероарильные производные сукцинамидов и их применение в качестве ингибиторов металлопротеиназы
DE60141347D1 (de) Zusammensetzungen zur beseitigung von unangenehmen gerüchen
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA199900239A1 (ru) Замещенные n-[аминоиминометил или аминометил) фенил] пропиламиды
EA200200253A1 (ru) Ингибиторы клеточной адгезии
EA199800106A1 (ru) Соединения и содержащие их фармацевтические композиции
DE69801048T2 (de) Fungizide trifluorophenyl-triazolopyrimidine
EA199900620A1 (ru) Фталазиноны
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
EA199800773A1 (ru) Производные пирролопирролона в качестве ингибиторов нейтрофильной эластазы
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
MY115071A (en) Efficacy enhancer for agricultural chemicals and agricultural chemical compositions
IL140070A0 (en) Benzamide derivatives and pharmaceutical compositions containing the same
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200101234A1 (ru) Новые производные аминотиазола, их получение и содержащие их фармацевтические композиции
EA200100140A1 (ru) Терапевтическая композиция на основе флавоноидов для применения в лечении опухолей цитотоксическими агентами
EA200100141A1 (ru) Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
EA200000092A1 (ru) Противоаллергические средства
EA199900534A1 (ru) Имидазопиридазины

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU